The University of Chicago Header Logo

Connection

Ted Skolarus to United States

This is a "connection" page, showing publications Ted Skolarus has written about United States.
Connection Strength

1.796
  1. Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities. JCO Oncol Pract. 2023 05; 19(5):e763-e772.
    View in: PubMed
    Score: 0.087
  2. Reframing Financial Incentives Around Reducing Readmission After Radical Cystectomy. Urology. 2020 08; 142:99-105.
    View in: PubMed
    Score: 0.072
  3. Inaugural Readmission Penalties for Total Hip and Total Knee Arthroplasty Procedures Under the Hospital Readmissions Reduction Program. JAMA Netw Open. 2019 11 01; 2(11):e1916008.
    View in: PubMed
    Score: 0.070
  4. Determinants of quality prostate cancer survivorship care across the primary and specialty care interface: Lessons from the Veterans Health Administration. Cancer Med. 2019 05; 8(5):2686-2702.
    View in: PubMed
    Score: 0.067
  5. De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT). Implement Sci. 2018 11 29; 13(1):144.
    View in: PubMed
    Score: 0.066
  6. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. J Oncol Pract. 2017 08; 13(8):e694-e702.
    View in: PubMed
    Score: 0.059
  7. Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials. 2017 04 18; 18(1):181.
    View in: PubMed
    Score: 0.059
  8. No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care. Urology. 2017 06; 104:77-83.
    View in: PubMed
    Score: 0.058
  9. Variation in readmission expenditures after high-risk surgery. J Surg Res. 2017 06 01; 213:60-68.
    View in: PubMed
    Score: 0.058
  10. Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease. Urology. 2017 06; 104:131-136.
    View in: PubMed
    Score: 0.058
  11. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014 Jul-Aug; 64(4):225-49.
    View in: PubMed
    Score: 0.048
  12. Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer. 2014 May 01; 120(9):1409-16.
    View in: PubMed
    Score: 0.047
  13. Quality of prostate cancer care among rural men in the Veterans Health Administration. Cancer. 2013 Oct 15; 119(20):3629-35.
    View in: PubMed
    Score: 0.045
  14. Monitoring quality of life among prostate cancer survivors: the feasibility of automated telephone assessment. Urology. 2012 Nov; 80(5):1021-6.
    View in: PubMed
    Score: 0.043
  15. Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology. 2011 Dec; 78(6):1345-9.
    View in: PubMed
    Score: 0.040
  16. Understanding fragmentation of prostate cancer survivorship care: implications for cost and quality. Cancer. 2012 Jun 01; 118(11):2837-45.
    View in: PubMed
    Score: 0.040
  17. Primary care perspectives on prostate cancer screening. Nurse Pract. 2011 Jun; 36(6):39-44.
    View in: PubMed
    Score: 0.039
  18. The delivery of prostate cancer care in the United States: implications for delivery system reform. J Urol. 2010 Dec; 184(6):2279-84.
    View in: PubMed
    Score: 0.037
  19. Improving urologic cancer care. Urol Oncol. 2010 Jul-Aug; 28(4):347-9.
    View in: PubMed
    Score: 0.036
  20. Regional differences in early stage bladder cancer care and outcomes. Urology. 2010 Aug; 76(2):391-6.
    View in: PubMed
    Score: 0.036
  21. Attitudes and barriers toward video visits in surgical care: Insights from a nationwide survey among surgeons. Surgery. 2024 Jul; 176(1):115-123.
    View in: PubMed
    Score: 0.024
  22. Industry Payments to Urologists and Urologic Advanced Practice Providers in 2021. Urology. 2023 10; 180:121-129.
    View in: PubMed
    Score: 0.023
  23. Evaluation of emergency department treat-and-release encounters after major gastrointestinal surgery. J Surg Oncol. 2023 Aug; 128(2):402-408.
    View in: PubMed
    Score: 0.022
  24. Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. Prostate Cancer Prostatic Dis. 2023 06; 26(2):287-292.
    View in: PubMed
    Score: 0.020
  25. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology. 2022 03; 161:50-58.
    View in: PubMed
    Score: 0.020
  26. Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. Urology. 2021 09; 155:70-76.
    View in: PubMed
    Score: 0.020
  27. Understanding Active Surveillance for Prostate Cancer. JCO Oncol Pract. 2021 11; 17(11):e1678-e1687.
    View in: PubMed
    Score: 0.019
  28. Variations in Persistent Use of Low-Value Breast Cancer Surgery. JAMA Surg. 2021 04 01; 156(4):353-362.
    View in: PubMed
    Score: 0.019
  29. Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees. Urology. 2021 09; 155:77-82.
    View in: PubMed
    Score: 0.019
  30. Aligning Urology Residency Training With Real-World Workforce Needs. J Surg Educ. 2021 May-Jun; 78(3):820-827.
    View in: PubMed
    Score: 0.019
  31. Demand for Surgical Procedures Following COVID-19: The Need for Operational Strategies That Optimize Resource Utilization and Value. Ann Surg. 2020 10; 272(4):e272-e274.
    View in: PubMed
    Score: 0.019
  32. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer. 2020 12 01; 126(23):5050-5059.
    View in: PubMed
    Score: 0.019
  33. Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration. Urol Oncol. 2020 09; 38(9):734.e1-734.e10.
    View in: PubMed
    Score: 0.018
  34. Resurrecting immortal-time bias in the study of readmissions. Health Serv Res. 2020 04; 55(2):273-276.
    View in: PubMed
    Score: 0.018
  35. Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2020 06; 18(3):201-209.e2.
    View in: PubMed
    Score: 0.018
  36. Implications of Cystectomy Travel Distance for Hospital Readmission and Survival. Clin Genitourin Cancer. 2019 12; 17(6):e1171-e1180.
    View in: PubMed
    Score: 0.017
  37. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer. J Urol. 2019 09; 202(3):518-524.
    View in: PubMed
    Score: 0.017
  38. Adoption of Abiraterone and Enzalutamide by Urologists. Urology. 2019 09; 131:176-183.
    View in: PubMed
    Score: 0.017
  39. Association Between Hospital Participation in Medicare Shared Savings Program Accountable Care Organizations and Readmission Following Major Surgery. Ann Surg. 2019 05; 269(5):873-878.
    View in: PubMed
    Score: 0.017
  40. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2019 07; 37(7):462-469.
    View in: PubMed
    Score: 0.017
  41. Urologist Practice Structure and Spending for Prostate Cancer Care. Urology. 2019 Aug; 130:65-71.
    View in: PubMed
    Score: 0.017
  42. Population Analysis of Male Urethral Stricture Management and Urethroplasty Success in the United States. Urology. 2019 01; 123:258-264.
    View in: PubMed
    Score: 0.016
  43. Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations. Cancer. 2018 08; 124(16):3364-3371.
    View in: PubMed
    Score: 0.016
  44. Predictors and Cost of Readmission in Total Knee Arthroplasty. J Arthroplasty. 2018 09; 33(9):2759-2763.
    View in: PubMed
    Score: 0.016
  45. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer. Urology. 2018 06; 116:68-75.
    View in: PubMed
    Score: 0.016
  46. The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. J Urol. 2018 09; 200(3):541-548.
    View in: PubMed
    Score: 0.016
  47. Association of the Hospital Readmissions Reduction Program With Surgical Readmissions. JAMA Surg. 2018 03 01; 153(3):243-250.
    View in: PubMed
    Score: 0.016
  48. Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care. Cancer. 2018 02 01; 124(3):563-570.
    View in: PubMed
    Score: 0.015
  49. The State of Men's Health Services in the Veterans Health Administration. Curr Urol Rep. 2017 Sep 18; 18(11):88.
    View in: PubMed
    Score: 0.015
  50. Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly. Eur Urol. 2018 04; 73(4):491-498.
    View in: PubMed
    Score: 0.015
  51. Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. Health Aff (Millwood). 2017 01 01; 36(1):108-115.
    View in: PubMed
    Score: 0.014
  52. Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. J Clin Oncol. 2016 10 10; 34(29):3586-3587.
    View in: PubMed
    Score: 0.014
  53. Implications of evolving delivery system reforms for prostate cancer care. Am J Manag Care. 2016 Sep; 22(9):569-75.
    View in: PubMed
    Score: 0.014
  54. Health Care Integration and Quality among Men with Prostate Cancer. J Urol. 2017 01; 197(1):55-60.
    View in: PubMed
    Score: 0.014
  55. A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy. J Urol. 2016 May; 195(5):1362-1367.
    View in: PubMed
    Score: 0.013
  56. Expectant management of veterans with early-stage prostate cancer. Cancer. 2016 Feb 15; 122(4):626-33.
    View in: PubMed
    Score: 0.013
  57. Veterans Affairs Telemedicine: Bringing Urologic Care to Remote Clinics. Urology. 2015 Aug; 86(2):255-60.
    View in: PubMed
    Score: 0.013
  58. Technology diffusion and prostate cancer quality of care. Urology. 2014 Nov; 84(5):1066-72.
    View in: PubMed
    Score: 0.012
  59. Validating electronic cancer quality measures at Veterans Health Administration. Am J Manag Care. 2014; 20(12):1041-7.
    View in: PubMed
    Score: 0.012
  60. Regional variation in quality of prostate cancer care. J Urol. 2014 Apr; 191(4):957-62.
    View in: PubMed
    Score: 0.011
  61. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013 Jun 26; 309(24):2587-95.
    View in: PubMed
    Score: 0.011
  62. Managed care and the diffusion of intensity-modulated radiotherapy for prostate cancer. Urology. 2012 Dec; 80(6):1236-42.
    View in: PubMed
    Score: 0.011
  63. Certificate of need regulations and the diffusion of intensity-modulated radiotherapy. Urology. 2012 Nov; 80(5):1015-20.
    View in: PubMed
    Score: 0.011
  64. Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood). 2012 Apr; 31(4):750-9.
    View in: PubMed
    Score: 0.010
  65. Understanding prostate cancer spending growth among Medicare beneficiaries. Urology. 2011 Feb; 77(2):326-31.
    View in: PubMed
    Score: 0.009
  66. Health care reform in 2010: transforming the delivery system to improve quality of care. World J Urol. 2011 Feb; 29(1):85-90.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.